Hospital Clínico San Carlos de Madrid -ko ikertzaileekin lankidetzan egindako argitalpenak (24)

2024

  1. Antitumoral activity of a CDK12 inhibitor in colorectal cancer through a liposomal formulation

    Biomedicine and Pharmacotherapy, Vol. 178

  2. Clinical and Immunologic Characteristics of Colorectal Cancer Tumors Expressing LY6G6D

    International Journal of Molecular Sciences, Vol. 25, Núm. 10

  3. Genomic and Immunologic Correlates in Prostate Cancer with High Expression of KLK2

    International Journal of Molecular Sciences, Vol. 25, Núm. 4

  4. In Silico Transcriptomic Expression of MSR1 in Solid Tumors Is Associated with Responses to Anti-PD1 and Anti-CTLA4 Therapies

    International Journal of Molecular Sciences, Vol. 25, Núm. 7

  5. Overcoming limitations for antibody-based therapies targeting γδ T (Vg9Vd2) cells

    Frontiers in Immunology, Vol. 15

2023

  1. Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned

    Journal of Hematology and Oncology, Vol. 16, Núm. 1

  2. Genomic Mapping of Epidermal Growth Factor Receptor and Mesenchymal–Epithelial Transition-Up-Regulated Tumors Identifies Novel Therapeutic Opportunities

    Cancers, Vol. 15, Núm. 12

  3. Guanylation Reactions for the Rational Design of Cancer Therapeutic Agents

    International Journal of Molecular Sciences, Vol. 24, Núm. 18

  4. Mapping Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers

    Current Oncology, Vol. 30, Núm. 3, pp. 2569-2581

2022

  1. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  2. Clinical considerations for the design of PROTACs in cancer

    Molecular Cancer, Vol. 21, Núm. 1

2021

  1. MZ1 co-operates with trastuzumab in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  2. Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation

    International Journal of Molecular Sciences, Vol. 22, Núm. 8

2020

  1. Checkpoint kinase 1 pharmacological inhibition synergizes with dna-damaging agents and overcomes platinum resistance in basal-like breast cancer

    International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-14

  2. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer

    Cellular Oncology, Vol. 43, Núm. 3, pp. 431-444

  3. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer

    Cancer Letters, Vol. 491, pp. 50-59

  4. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer

    Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 5, pp. 3117-3127

2019

  1. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 38, Núm. 1

  2. Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome

    OncoImmunology, Vol. 8, Núm. 10

  3. Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors

    PLoS ONE, Vol. 14, Núm. 4